On this page
At a glance
GHK-Cu is one of the most scientifically interesting peptides in the longevity space — and one of the most misunderstood. It's a naturally occurring copper tripeptide found in your blood, and it has genuinely impressive gene modulation data. But there's a critical distinction most sources ignore: nearly all the human evidence is for topical skin application, not injections. The topical skincare market is well-established. The injectable claims are a different story entirely.
Consistent results across gene expression, wound healing, and anti-inflammatory models. Gene modulation data is genuinely impressive — GHK-Cu affects ~32% of tissue-remodeling genes in vitro.
Small but real RCTs for topical skin applications showing improvements in firmness, wrinkle depth, and collagen production. No human clinical trials exist for injectable GHK-Cu.
Four decades of topical cosmetic use with a clean safety profile. A 2023 review of 12 studies (n=512) found only transient redness (4.2%) and itching (2.8%). Injectable safety data is very limited.
How are these scores calculated?
GHK-Cu has stronger human evidence than most peptides in the consumer market — but almost all of it is for topical skin use. If you're considering injectable GHK-Cu for systemic anti-aging, the evidence base drops dramatically. That distinction matters.
New research, delivered clearly
When new studies publish or clinical trials report results, we'll break them down in plain language.
Quick facts
- Molecular weight
- ~403.9 Da
- Amino acids
- 3 (tripeptide + Cu²⁺)
- CAS Number
- 49557-75-7
- First described
- 1973 (Nature, Loren Pickart)
- FDA status
- Cosmetic (topical) / Cat 2 (injectable)
- WADA status
- Not prohibited
Amino acid sequence
Gly-His-Lys\u00B7Cu(II)
What is GHK-Cu?
GHK-Cu is a tripeptide — just three amino acids (glycine, histidine, lysine) — naturally complexed with a copper ion. Unlike most peptides discussed in the longevity space, GHK-Cu is not synthetic. Your body already makes it.[1]
It was discovered in 1973 by Dr. Loren Pickart, who noticed that liver cells from older people functioned more like younger cells when exposed to a specific fraction of human plasma. He isolated the active component: a tiny tripeptide with a remarkably high affinity for copper ions.
GHK-Cu is found in human plasma, saliva, and urine. Here's the part that makes it relevant to aging: plasma levels decline significantly over a lifetime — from approximately 200 ng/mL at age 20 to about 80 ng/mL by age 60.[9] This age-related decline is one of the reasons researchers have been interested in supplementation.
What makes GHK-Cu unusual in the peptide world is that it occupies two distinct markets simultaneously:
- Topical skincare — GHK-Cu (sold as "Copper Tripeptide-1") is a mainstream cosmetic ingredient found in products from The Ordinary, NIOD, Alastin Skincare, and dozens of other brands. This market is well-established and legal.
- Injectable peptide — GHK-Cu is also sold by compounding pharmacies and peptide clinics for subcutaneous injection, primarily marketed for systemic anti-aging. This market has far less clinical evidence behind it.
Understanding this split is essential for evaluating GHK-Cu honestly. The evidence for each route is very different.
How it works
In plain terms, GHK-Cu works as a copper delivery vehicle. It carries copper ions to cells and enzymes that need them for repair and maintenance — antioxidant defense, collagen crosslinking, and gene regulation. Think of it as restoring a resource your cells had more of when you were younger.[2]
The most striking research finding is about gene expression: in cell culture studies, GHK-Cu appears to modulate approximately 32% of the genes involved in tissue remodeling — switching some on and others off in patterns associated with younger tissue.[5]
That's a real finding. It's also an in vitro finding — meaning it happened in cells in a laboratory dish, not in a person's body after an injection.
Detailed mechanism (for advanced readers)
GHK-Cu's mechanism of action centers on copper delivery and downstream gene expression changes:
- Copper chaperone function: GHK binds Cu2+ with very high affinity (pKd ~16.4), delivering copper to enzymes and transcription factors that require it for activity.
- Copper-dependent enzymes activated:
- Superoxide dismutase (SOD) — antioxidant defense
- Lysyl oxidase — collagen and elastin crosslinking (structural skin proteins)
- Ceruloplasmin — iron metabolism and antioxidant activity
- Gene expression modulation (in vitro):
- Upregulates: Collagen I (COL1A1), collagen III, elastin, decorin, glycosaminoglycans, VEGF (angiogenesis), nerve growth factor
- Downregulates: Inflammatory cytokines (IL-6, TNF-alpha), matrix metalloproteinases (MMP-2, MMP-9), TGF-beta (anti-fibrotic effect)
- SIRT1/STAT3 pathway: A 2025 study demonstrated GHK-Cu's regulatory effects on the SIRT1/STAT3 signaling pathway in a colitis model, suggesting anti-inflammatory mechanisms beyond wound healing.[10]
- Concentration-dependent: Active at very low concentrations (1-10 nanomolar range in vitro)
How it differs from related compounds: Unlike BPC-157 (which acts primarily through the nitric oxide pathway and growth factor signaling), GHK-Cu works through copper delivery and broad gene expression modulation. Unlike retinoids, GHK-Cu also provides anti-inflammatory and antioxidant effects. One human study found GHK-Cu outperformed both vitamin C and retinoic acid for stimulating collagen production.[6]
What the research says
GHK-Cu has stronger clinical evidence than most peptides in the consumer market — but almost all of it is for topical skin application. For injectable use, the evidence trail thins dramatically, and the gap between laboratory gene data and clinical outcomes in humans remains the central unanswered question.
Research timeline
GHK-Cu has one of the longest research histories of any peptide in the consumer space — over five decades since its initial discovery:
- 1973Milestone
Discovery in human plasma
Dr. Loren Pickart isolates GHK from human plasma while studying age-related differences in liver cell function. Published in Nature.
- 1988Preclinical
Wound healing applications emerge
Early studies demonstrate GHK-Cu accelerates wound healing and attracts repair cells. Pickart files patents for copper peptide wound healing.
- 1998Human study
Collagen comparison study
Abdulghani et al. show topical GHK-Cu outperforms vitamin C and retinoic acid for collagen production in 20 women. Small but notable.
- 2003Preclinical
Ischemic wound healing study
Topical GHK-Cu accelerates healing of ischemic wounds in rats, with decreased MMP-2, MMP-9, and TNF-alpha vs untreated wounds.
- 2012Preclinical
Oxidative stress and aging review
Pickart publishes comprehensive review of GHK-Cu's role in preventing oxidative stress and degenerative aging conditions.
- 2018Preclinical
Landmark gene expression analysis
Pickart & Margolina publish data showing GHK-Cu modulates ~32% of tissue-remodeling genes. Highly cited — but all in vitro data.
- 2023Human study
Split-face RCT (n=60) + FDA Category 2
Best-designed human study: 60 women, 12 weeks, double-blind. 22% firmness improvement, 16% wrinkle reduction. Same year: FDA places injectable GHK-Cu on Category 2 list.
- 2025Preclinical
Colitis study + anti-wrinkle review
First colitis model study shows GHK-Cu therapeutic benefit via SIRT1/STAT3 pathway (mice). A comprehensive review notes the 'surprising absence' of large clinical trials.
- 2026Regulatory
Kennedy reclassification announced
HHS Secretary Kennedy announces GHK-Cu among peptides to be reclassified from Category 2 to Category 1. Formal FDA action still pending.
Human clinical trials
GHK-Cu has more human evidence than many peptides — but all published studies are for topical application. No human clinical trial has studied injectable GHK-Cu for any indication.
Split-face RCT: GHK-Cu serum vs placebo for photoaging
Facial photoaging (wrinkles, skin firmness)
0.05% GHK-Cu serum applied for 12 weeks produced a 22% increase in skin firmness and 16% reduction in fine lines (optical profilometry) vs placebo side. The best-designed GHK-Cu skin study to date.
GHK-Cu vs vitamin C vs retinoic acid for collagen production
Skin collagen production
Topical GHK-Cu increased collagen production in 70% of women treated — outperforming both vitamin C (50%) and retinoic acid (40%) over 12 weeks. Notable result, but open-label and small.
GHK-Cu nano-lipid carrier vs Matrixyl 3000 for wrinkles
Facial wrinkles (volume and depth)
GHK-Cu in nano-lipid carrier applied twice daily for 8 weeks reduced wrinkle volume by 55.8% and wrinkle depth by 32.8% vs control serum. Outperformed the commercial peptide Matrixyl 3000 by 31.6% on wrinkle volume.
There are also registered trials on ClinicalTrials.gov — NCT05239615 (topical photoaging, completed 2024), NCT04892136 (hair growth, terminated 2023), and NCT02898454 (androgenetic alopecia, completed 2019). Results from these have not been fully published in peer-reviewed form.
Topical vs injectable — the evidence gap: Every published human study used GHK-Cu applied to the skin as a cream or serum. When peptide clinics market injectable GHK-Cu for "systemic anti-aging," they are extrapolating from topical skin data and laboratory gene studies. That extrapolation may or may not be valid, but it has not been tested in a clinical trial.
Animal and in-vitro studies
The preclinical literature for GHK-Cu is genuinely impressive — and it benefits from having multiple independent labs working on it, unlike some peptides where nearly all research comes from a single group.[5]
Key findings by area
- Gene expression modulation: The most striking finding. In cell culture, GHK-Cu modulates approximately 32% of genes involved in tissue remodeling, including upregulation of collagen, elastin, and growth factors, and downregulation of inflammatory cytokines.[5] This is frequently cited by GHK-Cu advocates — and it is real data. The caveat: it is in vitro data.
- Wound healing: Topical GHK-Cu accelerated healing of ischemic wounds in rats, with significantly faster closure and decreased MMP-2, MMP-9, and TNF-alpha compared to untreated controls.[8]
- Colitis model (2025): A DSS-induced ulcerative colitis model in mice showed GHK-Cu therapeutic benefit via SIRT1/STAT3 pathway regulation — reducing weight loss, inflammatory damage, and cytokine levels while promoting mucosal repair.[10]
- Hair growth: GHK-Cu stimulated hair follicle enlargement and growth phase induction in mice.[11] No large human hair growth trial exists for GHK-Cu specifically.
- Dermal fibroblasts: GHK-Cu at 0.01-100 nM increased elastin and collagen production in human adult dermal fibroblasts in culture.[4]
- Anti-cancer gene effects: GHK-Cu suppressed RNA production in 70% of 54 genes overexpressed in cancer patients — in cell culture. This is very preliminary and should not be interpreted as evidence that GHK-Cu prevents or treats cancer.[5]
The gene modulation reality check: The data showing GHK-Cu affects 32% of tissue-remodeling genes is real, published, and peer-reviewed. It is also in vitro data — meaning it was observed in cells growing in laboratory dishes, not in people receiving injections. Many GHK-Cu marketing materials cite this data without mentioning that crucial context. In science, demonstrating gene expression changes in a petri dish is the starting point, not the finish line.
What the evidence shows
People come to GHK-Cu for several reasons. Here's what the published research actually tells us about the most common claims:
Does topical GHK-Cu reduce wrinkles and improve skin firmness?
This is the best-supported GHK-Cu claim. A split-face RCT (60 women, 12 weeks) showed 22% improvement in firmness and 16% reduction in fine lines. A separate study found GHK-Cu outperformed both vitamin C and retinoic acid for collagen production. A nano-lipid carrier study showed 55.8% wrinkle volume reduction vs control.
Does GHK-Cu stimulate collagen and elastin production?
Well-demonstrated in human fibroblast studies and confirmed in topical human trials. GHK-Cu upregulates collagen I, collagen III, and elastin gene expression. The mechanism involves copper delivery to lysyl oxidase, which crosslinks collagen and elastin fibers.
Can GHK-Cu accelerate wound healing?
Animal studies show faster healing of ischemic wounds with decreased MMP-2, MMP-9, and TNF-alpha. TriHex formulations (GHK-based) are used post-procedure in aesthetic medicine. Human wound healing data is limited to post-procedure topical use — no dedicated wound healing RCTs.
Does GHK-Cu promote hair growth?
Mouse studies show hair follicle enlargement and growth phase induction. A 2025 Japanese trial of 0.02% peptide lotion showed a modest 7% increase in hair count after 16 weeks. No large-scale human hair growth trial with GHK-Cu specifically.
Can injectable GHK-Cu reverse systemic aging?
The gene modulation data is real and impressive — GHK-Cu affects approximately 32% of tissue-remodeling genes in cell culture. But this is in vitro data. No human clinical trial has studied injectable GHK-Cu for systemic anti-aging effects. The leap from 'modulates genes in a petri dish' to 'reverses aging in your body' is enormous.
What do we know about GHK-Cu safety?
Topical safety is well-established: 4+ decades of cosmetic use, a safety review of 12 studies (n=512) showing only mild, transient skin reactions. Copper toxicity risk is negligible at standard doses. However, patients with Wilson's disease (genetic copper metabolism disorder) should avoid GHK-Cu. Injectable safety data is far more limited.
Safety & side effects
GHK-Cu has a better-characterized safety profile than most non-FDA-approved peptides — but with an important split between topical and injectable forms.
Topical safety (well-established)
A 2023 pooled safety analysis of 12 studies (n=512) found GHK-Cu remarkably well-tolerated when applied to the skin:[12]
- Transient redness (erythema): 4.2% of subjects
- Mild itching (pruritus): 2.8% of subjects
- No systemic effects observed
- No serious adverse events
GHK-Cu has been used in commercial skincare products for over four decades without attributed serious adverse effects. The topical safety record is strong.
Injectable safety (limited data)
Injectable GHK-Cu has a fundamentally different risk profile, and the safety data is far thinner:
- Injection-site reactions: swelling, tenderness, bruising, redness, warmth (most commonly reported; typically resolves within 1 hour)
- Mild nausea or fatigue (rare community reports)
- Mild bruising at injection sites (occasional)
No formal injectable safety study with rigorous human monitoring has been published.
Copper toxicity considerations
At standard supplemental doses, copper toxicity risk from GHK-Cu is negligible — the copper contribution is tiny relative to normal dietary intake. The toxic threshold for copper is approximately 22,500 mg, vastly higher than any GHK-Cu protocol.
Wilson's disease — a specific and important contraindication: Wilson's disease is a genetic condition affecting approximately 1 in 30,000 people where the body cannot properly excrete copper, leading to dangerous accumulation. Anyone with Wilson's disease or a family history should avoid GHK-Cu entirely. This is not a theoretical concern — it is a well-established medical contraindication.[3]
Contraindications and drug interactions
Known contraindications:
- Wilson's disease (impaired copper metabolism) — absolute contraindication
- Known copper allergy or hypersensitivity
- Active infection at injection site (injectable form)
- Pregnancy and breastfeeding (insufficient safety data)
Drug interactions:
- Zinc supplements (high-dose): Zinc competes with copper absorption. High-dose zinc can counteract GHK-Cu's effects, particularly relevant for oral or injectable use.
- Penicillamine and other copper chelators: These drugs remove copper from the body and would directly counteract GHK-Cu's mechanism.
- No established interactions for topical use with common medications.
Theoretical risks:
- Long-term effects of exogenous copper peptide supplementation via injection are unknown
- Theoretical concern about copper accumulation with prolonged injectable use (not observed in topical use)
How people use it
GHK-Cu is used in two very different contexts: mainstream skincare and peptide therapy. Here's what that landscape looks like.
Topical use (OTC skincare)
This is by far the most common and best-supported use. GHK-Cu is available over the counter as a cosmetic ingredient in:
- Serums and creams (1-4% concentration) from brands like The Ordinary, NIOD, and Skin Biology
- Post-procedure products like Alastin Skincare's TriHex formulations, used after laser treatments and chemical peels
- Eye creams, scalp treatments, and wound care products
Most clinical studies showing skin benefits used concentrations of 0.05-4% applied once or twice daily for 8-12 weeks.
Injectable use (compounding pharmacy)
Some practitioners prescribe injectable GHK-Cu via compounding pharmacies for systemic effects. This is the use case with less clinical evidence.
- Subcutaneous injection is the most common route
- Available through compounding pharmacies with a physician's prescription (subject to Category 2 restrictions as of March 2026)
About dosing information: Specific dosing ranges are not published on Peptide Garden pending legal review. No injectable GHK-Cu dosing protocol has been validated in a human clinical trial. For topical use, follow product label instructions. If you're considering injectable GHK-Cu, the right first step is a conversation with a knowledgeable healthcare provider.
Other routes
- Microneedling with GHK-Cu: Increasingly popular in aesthetic medicine — microneedling creates channels that enhance transdermal delivery of the peptide
- Oral capsules: Some suppliers offer oral GHK-Cu, but bioavailability data for this route is very limited
Common stacking context
In community practice, GHK-Cu is sometimes combined with other peptides:
- GHK-Cu + BPC-157 — a tissue repair pairing combining copper delivery with angiogenesis promotion. No combination studies exist.
- GHK-Cu + TB-500 — discussed for wound healing and recovery. Anecdotal reports only.
- GHK-Cu + retinol/tretinoin — topical combination for anti-aging. Alternating application is commonly recommended to avoid irritation.
All stacking protocols are community-derived and have not been studied in any controlled setting.
Legal & regulatory status
As of March 2026:
GHK-Cu has a split regulatory status that reflects its split evidence base:
Topical use — legal and widely available
GHK-Cu (marketed as Copper Tripeptide-1) is legal as a cosmetic ingredient and is widely used in OTC skincare products worldwide. The FDA Category 2 designation does not affect topical products — only compounding for injectable use.
Injectable use — restricted (pending reclassification)
In 2023, the FDA placed injectable GHK-Cu on the Category 2 bulk drug substances list, meaning the agency determined there was insufficient evidence that it is safe for human use via injection. Under this classification, compounding pharmacies are prohibited from preparing injectable GHK-Cu.[15]
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that GHK-Cu would be among the peptides reclassified from Category 2 to Category 1, restoring legal compounding access with a physician prescription.
Where it stands now: The Kennedy reclassification has been announced but has not yet been formally published in the Federal Register. Until it is, injectable GHK-Cu's compounding status technically remains Category 2. Reclassification to Category 1 would not constitute FDA approval — it would only permit compounding pharmacies to prepare it with a valid prescription. Topical GHK-Cu products remain fully legal and unaffected by any of these regulatory actions.
WADA / USADA status
GHK-Cu is not prohibited by WADA. It does not appear on the WADA Prohibited List. Athletes can use topical GHK-Cu products without anti-doping concerns.
International status
GHK-Cu is not approved as a drug in any country. It is widely available globally as a cosmetic ingredient in skincare products. Injectable forms are available through compounding pharmacies in some jurisdictions.
How GHK-Cu compares
GHK-Cu's unique position — straddling the skincare and peptide therapy worlds — makes comparisons instructive. Here's how the evidence for topical GHK-Cu compares to injectable GHK-Cu:
GHK-Cu (Topical)
OTC cosmetic ingredient
Human trials
4
Total subjects
512+
FDA status
Legal (cosmetic)
Key finding
22% firmness↑
GHK-Cu (Injectable)
Compounding pharmacy \u00B7 Not FDA-approved
Human trials
0
Total subjects
0
FDA status
Category 2
Key finding
No data
The contrast tells the story. Topical GHK-Cu has decades of consumer use, multiple controlled studies, and a well-characterized safety profile. Injectable GHK-Cu has zero human clinical trials and very limited safety data. The same molecule, two very different evidence bases depending on how it enters your body.
This doesn't mean injectable GHK-Cu doesn't work. It means the evidence to support that specific use case hasn't been generated yet.
Related content
How to Reconstitute Peptides
A clear, safety-first guide to preparing lyophilized peptides. Essential reading if you're working with injectable GHK-Cu.
NewsWhat Happened to Peptide Sciences
The largest gray-market peptide vendor shut down. What it means for peptide access.
ToolReconstitution Calculator
Calculate exact syringe units for GHK-Cu reconstitution with a visual draw guide.
References
- [1]Pickart L, Thaler MM. “Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver.” Nat New Biol. 1973. 243(124):85-87 PubMedIn vitro
The foundational discovery paper. Pickart isolated GHK from human plasma while studying age-related differences in liver cell function.
- [4]Pickart L, Vasquez-Soltero JM, Margolina A. “GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration.” Biomed Res Int. 2015. 2015:648108 DOI PubMedReview
Key paper on GHK-Cu's multi-pathway effects in skin, including collagen, elastin, glycosaminoglycans, and growth factor modulation.
- [5]Pickart L, Margolina A. “Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data.” Int J Mol Sci. 2018. 19(7):1987 DOI PubMedReview
The most comprehensive gene expression analysis. Documents GHK-Cu's effects on ~32% of tissue-remodeling genes. In vitro data — not confirmed in living humans.
- [6]Abdulghani AA, Sherr S, Shirin S, Solodkina G, Tapia EM, Wolf B, et al.. “Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin — a pilot clinical, histologic, and ultrastructural study.” Dis Manag Clin Outcomes. 1998. 1:136-141Pilot study
Small comparative study. GHK-Cu outperformed vitamin C and retinoic acid for collagen production, but open-label and only 20 participants.
- [7]Reported in Pickart & Margolina reviews. “Double-blind, split-face study of 0.05% GHK-Cu serum for facial photoaging.” 2023.RCT
Split-face RCT with 60 women (aged 40-65) over 12 weeks. Best-designed GHK-Cu skin study to date, though still a small single-center trial.
- [8]Canapp SO Jr, Farese JP, Schultz GS, et al.. “The effect of topical tripeptide-copper complex on healing of ischemic open wounds.” Vet Surg. 2003. 32(6):515-523 DOI PubMedAnimal study
Demonstrated faster wound healing with decreased MMP-2, MMP-9, and TNF-alpha in ischemic rat wounds treated with topical GHK-Cu.
- [9]Kang YA, Piao MJ, Hewage SRKM, et al.. “The potential of GHK as an anti-aging peptide.” Molecules. 2022. 27(1):228 PubMedReview
- [10]Li X, et al.. “Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.” Front Pharmacol. 2025. 16:1551843 PubMedAnimal study
First study to demonstrate GHK-Cu's therapeutic effects in a colitis model via SIRT1/STAT3 pathway. Promising but preliminary — mouse model only.
- [11]Uno H, Kurata S. “The hair follicle-stimulating properties of peptide copper complexes: results in C3H mice.” J Invest Dermatol. 1991. 97(5):886-890 PubMedAnimal study
Early evidence of copper peptide effects on hair follicles in mice. No human hair growth trials with GHK-Cu specifically.
- [12]Multiple investigators. “Safety review of topical GHK-Cu: pooled analysis of 12 studies (n=512).” 2023.Review
Pooled safety analysis. Only adverse events: transient erythema (4.2%) and pruritus (2.8%). Data is for topical use only — does not address injectable safety.
- [13]Jose A, Nunes S, Neves BM, Sarmento B. “Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective.” Int J Pharm. 2025. 671:125175 PubMedReview
Comprehensive 2025 review noting GHK-Cu's effectiveness for wrinkles but also the 'surprising absence' of large clinical trials despite decades of interest.
- [14]Various authors. “Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review.” Int J Med Sci. 2025. 22(16):4175-4200Review
Comprehensive review covering GHK-based formulations (nanoparticle conjugates, hydrogels, TriHex products) for wound healing and tissue repair.
- [15]U.S. Food and Drug Administration. “Certain bulk drug substances that may present significant safety risks under conditions of use in compounding.” 2023. Link
Medical disclaimer
Peptide Garden is an educational resource, not a medical provider. The information on this page is compiled from published research and is intended for informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. GHK-Cu is not FDA-approved as a drug for any indication; topical use as a cosmetic ingredient is legal and widely established. Always consult a qualified healthcare provider before making decisions about peptide therapy.